Philippines - English - FDA (Food And Drug Administration)

amn life science pvt ltd.; importer: biocare lifesciences inc.; distributor: progen pharmaceutical distributors - ketoanalogues , essential amino acids - film-coated tablet - each film-coated tablet contains: calcium 4-methyl-2-oxo-valerate (a-ketoanalogue to leucine, calcium salt)-101mg calcium-3-methyl-2-oxo-butyrate (a -ketoanalogue to valine, calcium salt)-86mg calcium-2-oxo-3-phenylpropionate (a -ketoanalogue to phenylalanine, calcium salt)-68mg calcium 3-methyl-2-oxo-valerate (a -ketoanalogue to isoleucine, calcium salt)-67mg calcium-dl-2-hydroxy-4(methylthio) butyrate (a -ketoanalogue to methionine, calcium salt-59mg l-lysine acetate-105mg l-threonine-53mg l-histidine-38mg l-tyrosine-30mg l-tryptophan-23mg

Philippines - English - FDA (Food And Drug Administration)

biocare lifesciences, inc.; distributor: progen pharmaceutical distributors - pregabalin - capsule - 75 mg

Philippines - English - FDA (Food And Drug Administration)

biocare lifesciences, inc.; distributor: progen pharmaceutical distributors - cefuroxime (as axetil) - film-coated tablet - 500 mg

United States - English - NLM (National Library of Medicine)

university of texas md anderson cancer center - human cord blood hematopoietic progenitor cell (unii: xu53vk93mc) (human cord blood hematopoietic progenitor cell - unii:xu53vk93mc) - hematopoietic progenitor cell (hpc), cord blood, is an allogeneic cord blood hematopoietic progenitor cell therapy indicated for use in unrelated donor hematopoietic progenitor stem cell transplantation procedures in conjunction with an appropriate preparative regimen for hematopoietic and immunologic reconstitution in patients with disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment. the benefit-risk assessment for an individual patient depends on the patient characteristics, including disease, stage, risk factors, and specific manifestations of the disease, on characteristics of the graft, and on other available treatments or types of hematopoietic progenitor cells. none. risk summary there are no data with hpc, cord blood use in pregnant women to inform a product-associated risk.  animal reproduction studies have not been conducted with hpc, cord blood. in the u.s. general population, the estimated background risk of major birth defects and misc